Healthy
Conditions
Brief summary
This study will assess the absolute bioavailability of a single oral dose of lesinurad and evaluate the pharmacokinetic (PK) parameters of lesinurad and \[14C\]lesinurad in healthy adult male subjects.
Detailed description
In this study a single dose of lesinurad will be administered after an overnight fast followed by a single 15-minute infusion of a radiolabeled intravenous micro tracer dose of \[14C\]lesinurad to assess the in vivo performance of lesinurad.
Interventions
DRUG[14C]lesinurad (100 μg per 10 mL)
DRUGLesinurad 400 mg
Sponsors
Ardea Biosciences, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject has a body weight ≥ 50 kg (110 lbs) and body mass index ≥ 18 and ≤ 30 kg/m2. * Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment
Exclusion criteria
* Subject has a history or suspicion of kidney stones. * Subject has undergone major surgery within 3 months prior to Screening. * Subject donated blood or experienced significant blood loss (\>450 mL) within 12 weeks prior to Screening or gave a plasma donation within 4 weeks prior to Screening. * Subject has inadequate venous access or unsuitable veins for repeated venipuncture. * Subject does not have a normal or clinically acceptable physical examination, per the Investigator's judgment. * Subject has clinically relevant abnormalities in blood pressure, heart rate, or body temperature, per the Investigator's judgment. * Subject has Screening clinical safety laboratory parameters (serum chemistry, hematology, or urinalysis) that are outside the normal limits and are considered clinically significant by the Investigator. * Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the Investigator's judgment. * Subject has a Screening serum urate level \> 7 mg/dL. * Subject had radiation exposure that exceeds 5 mSv in the last 12 months or 10 mSv in the last 5 years. This includes radiation exposure from the present study or other clinical studies, including diagnostic X-rays and other medical exposures but excluding exposure to background radiation. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characteristics of bioavailability in terms of lesinurad Pharmacokinetics (PK) profile from plasma. | Day 1 to Day 5 | PK profile in terms of maximum observed concentration (Cmax), time of occurrence of maximum observed concentration (Tmax), area under the concentration-time curve (AUC), apparent terminal half-life (t½), mean residence time (MRT), mean absorption time (MAT), and absolute bioavailability (F). |
| PK profile of [14C]lesinurad from plasma | Day 1 to Day 5 | PK profile in terms of Cmax, AUC, t½, MRT, total body clearance (CL), and volume of distribution at steady state (Vss). |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters | 5 weeks |
Countries
United States
Outcome results
None listed